RVNC Revance Therapeutics, Inc. Stock Quote

RVNC [NASD]

Index	-	P/E	-	EPS (ttm)	-4.04	Insider Own	1.90%	Shs Outstand	68.33M	Perf Week	-1.86%
Market Cap	1.03B	Forward P/E	-	EPS next Y	-2.99	Insider Trans	0.00%	Shs Float	64.19M	Perf Month	1.64%
Income	-274.00M	PEG	-	EPS next Q	-0.86	Inst Own	84.30%	Short Float	11.13%	Perf Quarter	-29.94%
Sales	89.80M	P/S	11.42	EPS this Y	14.30%	Inst Trans	2.76%	Short Ratio	9.11	Perf Half Y	-14.94%
Book/sh	0.37	P/B	38.46	EPS next Y	12.20%	ROA	-45.80%	Target Price	28.78	Perf Year	-51.73%
Cash/sh	3.64	P/C	3.90	EPS next 5Y	11.60%	ROE	-273.70%	52W Range	11.27 - 33.83	Perf YTD	-12.81%
Dividend	-	P/FCF	-	EPS past 5Y	-5.60%	ROI	-78.70%	52W High	-57.94%	Beta	0.94
Dividend %	-	Quick Ratio	3.90	Sales past 5Y	203.90%	Gross Margin	69.80%	52W Low	26.26%	ATR	0.85
Employees	495	Current Ratio	4.00	Sales Q/Q	90.20%	Oper. Margin	-	RSI (14)	52.45	Volatility	5.79% 5.87%
Optionable	Yes	Debt/Eq	17.64	EPS Q/Q	12.40%	Profit Margin	-	Rel Volume	1.07	Prev Close	14.55
Shortable	Yes	LT Debt/Eq	16.90	Earnings	May 10 AMC	Payout	-	Avg Volume	784.62K	Price	14.23
Recom	1.80	SMA20	6.73%	SMA50	-2.80%	SMA200	-14.39%	Volume	838,427	Change	-2.20%

Oct-25-21

Downgrade

Wells Fargo

Overweight → Equal Weight

$35 → $17

Oct-15-20

Reiterated

Needham

Buy

$36 → $42

Aug-11-20

Resumed

Mizuho

Buy

$32

Mar-23-20

Downgrade

Goldman

Buy → Neutral

$32 → $15

Dec-02-19

Initiated

Goldman

Buy

Oct-30-19

Upgrade

Wells Fargo

Market Perform → Outperform

$20

Jun-11-19

Initiated

Barclays

Overweight

$28

Feb-15-19

Initiated

Wells Fargo

Market Perform

Feb-14-19

Initiated

H.C. Wainwright

Buy

$25

Jan-29-19

Initiated

Stifel

Buy

$50

Nov-16-18

Upgrade

Guggenheim

Neutral → Buy

Sep-17-18

Downgrade

JMP Securities

Mkt Outperform → Mkt Perform

Apr-20-18

Reiterated

Mizuho

Buy

$54 → $48

Mar-27-18

Initiated

Needham

Buy

$42

Mar-05-18

Initiated

Goldman

Buy

$60

Jan-09-18

Downgrade

Guggenheim

Buy → Neutral

Dec-06-17

Reiterated

Mizuho

Buy

$37 → $54

Dec-06-17

Initiated

Guggenheim

Buy

$42

Nov-27-17

Initiated

Barclays

Overweight

$31

Nov-17-17

Initiated

Mizuho

Buy

$37

Jun-15-22 08:19AM	Is Revance Therapeutics (RVNC) a Worthy Investment Pick? Insider Monkey
May-23-22 08:00AM	Revance to Participate in the William Blair 42nd Annual Growth Stock Conference Business Wire
May-17-22 06:46AM	Bullish insiders bet US$1.0m on Revance Therapeutics, Inc. (NASDAQ:RVNC) Simply Wall St. +5.84%
May-10-22 05:45PM	Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update Business Wire
May-05-22 06:45PM	Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates Zacks
May-03-22 08:00AM	Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022 Business Wire
Apr-21-22 04:05PM	Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines Business Wire
Apr-08-22 03:00PM	Investors bid Revance Therapeutics (NASDAQ:RVNC) up US$52m despite increasing losses YoY, taking three-year CAGR to 13% Simply Wall St.
Mar-28-22 08:00AM	Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting Business Wire
Mar-22-22 05:03AM	Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 8.7% Jump Turn into More Strength? Zacks
Mar-21-22 08:00AM	Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management Business Wire +8.67%
Mar-08-22 08:00AM	Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA Business Wire +5.63%
Mar-02-22 08:00AM	Revance to Participate in the Cowen 42nd Annual Health Care Conference Business Wire
Feb-28-22 04:05PM	Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update Business Wire
Feb-23-22 02:06PM	State board grants incentives to four jobs deals, including a California HQ transplant doubling its pledged headcount American City Business Journals
Feb-22-22 08:00AM	Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022 Business Wire
Feb-21-22 03:00PM	Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release Zacks
Feb-08-22 01:38PM	CIBC Asset Management Inc Buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, ... GuruFocus.com
Feb-07-22 01:50PM	Could The Revance Therapeutics, Inc. (NASDAQ:RVNC) Ownership Structure Tell Us Something Useful? Simply Wall St.
Jan-25-22 01:38PM	Genesee Capital Advisors, LLC Buys SPDR Portfolio TIPS ETF, Synchrony Financial, Archer-Daniels ... GuruFocus.com
11:02AM	Should You Remain Optimistic in Your Revance Therapeutics (RVNC) Position? Insider Monkey
Jan-18-22 04:05PM	Revance Receives Clarity on Path to Resubmission of the BLA for DaxibotulinumtoxinA for Injection Following Type A Meeting with FDA Business Wire -6.84%
Jan-13-22 01:38PM	Wedbush Securities Inc Buys iShares 1-3 Year Treasury Bond ETF, First Trust Low Duration ... GuruFocus.com
Jan-07-22 08:00AM	Revance Provides Preliminary Fourth Quarter and Full Year 2021 Financial Results and a Corporate Update Business Wire +6.21%
Dec-31-21 07:13PM	Upcoming Deadline Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm NewMediaWire
06:13PM	Revance Therapeutics Update NewMediaWire
02:50PM	UPCOMING DEADLINE ALERT: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm PR Newswire
01:00PM	SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm ACCESSWIRE
Dec-30-21 11:15PM	ALERT: Revance Therapeutics, Inc. Investors with Significant Losses Have Opportunity to Lead Class Action Lawsuit - RVNC PR Newswire
10:00PM	FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Revance Therapeutics, Inc. - RVNC PR Newswire
06:01PM	Revance Therapeutics Class Action Reminder NewMediaWire
05:36PM	Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for Revance Therapeutics, Inc. Investors in Securities Fraud Class Action Lawsuit ACCESSWIRE
04:00PM	Revance Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information ACCESSWIRE
03:23PM	Investor Action Notice: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm NewMediaWire
11:15AM	Thornton Law Firm Reminds Revance Therapeutics (Rvnc) Investors of Securities Class Action Lawsuit ACCESSWIRE
09:36AM	RVNC SHAREHOLDER NOTICE: Hagens Berman Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firms Attorneys, Securities Fraud Class Action Pending ACCESSWIRE
09:30AM	INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm ACCESSWIRE
Dec-29-21 11:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC PR Newswire
07:01PM	REVANCE THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC PR Newswire
06:01PM	Revance Therapeutics Shareholder Notice NewMediaWire
04:21PM	Investor Action Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm NewMediaWire
03:15PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Revance Therapeutics, Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNC ACCESSWIRE
10:15AM	SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm ACCESSWIRE
Dec-28-21 06:01PM	Revance Therapeutics Shareholder Alert NewMediaWire
04:00PM	REVANCE THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC ACCESSWIRE
02:36PM	Shareholder Action Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm NewMediaWire
11:30AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Revance Therapeutics, Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNC ACCESSWIRE
10:00AM	SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm ACCESSWIRE
Dec-27-21 05:58PM	Revance Therapeutics Deadline Alert NewMediaWire
03:38PM	Investor Action Notice: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm NewMediaWire
03:15PM	Revance Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information ACCESSWIRE
02:22PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Revance Therapeutics, Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNC PR Newswire
12:30PM	REVANCE THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC ACCESSWIRE
11:00AM	INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm ACCESSWIRE
Dec-26-21 10:40PM	SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm ACCESSWIRE
05:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC ACCESSWIRE
08:26AM	Revance Therapeutics Deadline Alert NewMediaWire
Dec-25-21 06:55PM	RVNC DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP - Important LP February 8, 2022 Deadline Reminder for Revance Therapeutics, Inc. PR Newswire
08:22AM	Revance Therapeutics Update NewMediaWire
Dec-24-21 03:20PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firms Attorneys, Securities Fraud Class Action Filed ACCESSWIRE
01:44PM	Investor Action Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm NewMediaWire
11:00AM	SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm ACCESSWIRE
Dec-23-21 11:00PM	REVANCE THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC ACCESSWIRE
09:52PM	ROSEN, A TOP RANKED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important February 8 Deadline in Securities Class Action - RVNC PR Newswire
06:58PM	Revance Therapeutics Class Action Reminder NewMediaWire
05:10PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Revance Therapeutics, Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNC ACCESSWIRE
02:15PM	RVNC INVESTOR ALERT: Thornton Law Firm Reminds Revance Therapeutics Investors of Securities Class Action Lawsuit ACCESSWIRE
09:30AM	SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm ACCESSWIRE
Dec-22-21 08:02PM	Moore Kuehn, PLLC Encourages Investors of SNBR, RKT, or RVNC Contact Law Firm PR Newswire
06:49PM	Revance Therapeutics Shareholder Notice NewMediaWire
05:00PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Revance Therapeutics, Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 RVNC ACCESSWIRE
04:34PM	Investor Action Notice: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm NewMediaWire
02:32PM	DEADLINE ALERT for RVNC, RAAS, ORGO, and XCUR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
09:40AM	INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm ACCESSWIRE
Dec-21-21 11:32PM	FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CTXS, NVAX, RVNC and STNE GlobeNewswire
09:35PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC PR Newswire
08:05PM	RVNC NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit GlobeNewswire
06:57PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Revance Therapeutics, Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNC PR Newswire
06:45PM	Revance Therapeutics Shareholder Alert NewMediaWire
05:00PM	REVANCE THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC ACCESSWIRE
03:40PM	Investor Action Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm NewMediaWire
01:00PM	Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) Business Wire
11:00AM	RVNC Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Revance Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm ACCESSWIRE
09:20AM	SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm ACCESSWIRE
06:06AM	RVNC Shareholders: Robbins LLP Reminds Investors of Class Action Against Revance Therapeutics, Inc. (RVNC) Business Wire
Dec-20-21 11:01PM	SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS HOOD, MARA, RAAS, RVNC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire
07:20PM	Kessler Topaz Meltzer & Check, LLP Reminds Revance Therapeutics, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Significant Losses to Contact the Firm ACCESSWIRE
06:53PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline RVNC GlobeNewswire
05:53PM	Revance Therapeutics Deadline Alert NewMediaWire
03:41PM	Shareholder Action Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm NewMediaWire
03:30PM	REVANCE THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC ACCESSWIRE
11:00AM	RVNC Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Revance Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm Business Wire
11:00AM	Revance Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information ACCESSWIRE
11:00AM	INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm ACCESSWIRE
10:00AM	Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) Business Wire
09:40AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Revance Therapeutics, Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNC ACCESSWIRE
09:30AM	RVNC CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firms Attorneys, Securities Fraud Class Action Pending ACCESSWIRE
Dec-19-21 09:00PM	REVANCE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. and Encourages Investors to Contact the Firm GlobeNewswire
06:32PM	RVNC DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit ACCESSWIRE

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Russell Angus C.	Director	Dec 13	Buy	15.74	6,400	100,741	26,913	Dec 15 08:17 PM
Rankin Aubrey	President, Innovation & Tech	Dec 03	Buy	14.43	30,000	432,876	95,463	Dec 06 08:34 PM
Foley Mark J	CEO	Nov 29	Buy	12.90	40,000	515,924	110,913	Nov 29 09:24 PM
Moxie Dwight	SVP, GC & Secretary	Sep 27	Sale	30.00	1,675	50,250	47,804	Sep 28 09:23 PM
Rankin Aubrey	President, Innovation & Tech	Aug 16	Sale	26.34	9,364	246,659	65,463	Aug 17 06:20 PM
Rankin Aubrey	President, Innovation & Tech	Jul 28	Sale	30.06	54,332	1,632,960	154,302	Jul 30 08:57 PM
Rankin Aubrey	President, Innovation & Tech	Jul 26	Sale	29.72	55,382	1,645,953	355,943	Jul 28 09:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience